BC CANCER
Provincial Health Services Authority

Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Treatment Programs Under Consideration

The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found on the Cancer Drug Manual Drug Index website.

ULYNIV & ULYNIV4

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Adverse Events

Nivolumab	Treatment of **relapsed or refractory Hodgkin Lymphoma**	Possible adverse events **(any grade)**:
		• Immune-mediated adverse reactions: (see SCIMMUNE Resources)
		  ○ Skin:
		  ▪ Rash
		  ▪ Pruritus
		  ○ Enterocolitis:
		  ▪ Diarrhea
		  ▪ Abdominal pain
		  ○ Endocrine:
		  ▪ Hypothyroidism/hyperthyroidism
		  ▪ Fatigue
		  ○ Pulmonary:
		  ▪ Pneumonitis
		  ○ Hepatic:
		  ▪ Elevated alanine aminotransferase (ALT)
		  ○ Renal
		  ▪ Increased serum creatinine
		• Infusion-related reactions

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** low emetogenicity
- **Infusion reaction:** If prior reactions to nivolumab:
  diphenhydramine 50 mg PO, acetaminophen 325 to 975 mg PO, and hydrocortisone 25 mg IV

Dosing and Schedule:

- **IV nivolumab** 3 mg/kg (maximum dose 240 mg) every 2 weeks until disease progression or unacceptable toxicity
  - To be given over 30 minutes using a 0.2 or 0.22 micron in-line filter

OR

- **IV nivolumab** 6 mg/kg (maximum dose 480 mg) every 4 weeks until disease progression or unacceptable toxicity
  - To be given over 30 minutes using a 0.2 or 0.22 micron in-line filter

Additional Protocol Information:

- Optional weekly nursing assessment

ULYVENETOR

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Adverse Events
Venetoclax plus Rituximab	Treatment of patients with **relapsed or refractory chronic lymphocytic leukemia (CLL)** or **small lymphocytic lymphoma (SLL)**.	Possible adverse events **(any grade)**: • Infusion-related reactions • Neutropenia • Diarrhea • Nausea • Anemia • Upper respiratory tract infection • Thrombocytopenia • Fatigue Possible adverse events **(≥ grade 3):** • Pneumonia • Febrile neutropenia • Autoimmune hemolytic anemia • Tumour lysis syndrome (TLS)

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** low emetogenicity
- **For IV rituximab:**
  diphenhydramine 50 mg PO and acetaminophen 650- 975 mg PO prior to rituximab and then q 4 h during the infusion, if the infusion exceeds 4 hours
- **For SC rituximab:**
  diphenhydramine 50 mg PO and acetaminophen 650- 975 mg PO prior to rituximab

Dosing and Schedule:

Ramp-up Phase		
Oral Venetoclax*	20mg daily	Week 1
	50mg daily	Week 2
	100 mg daily	Week 3
	200 mg daily	Week 4
	400 mg daily	Week 5

Combination Therapy ** (post Ramp-up)		
Oral Venetoclax + IV Rituximab	400 mg daily 375 mg/m2 Day 1	Cycle 1
Oral Venetoclax + IV Rituximab *OR* SC Rituximab	400 mg daily 500 mg/m2 Day 1 *OR* 1600 mg Day 1	Cycles 2 - 6

Maintenance Therapy		
Oral Venetoclax	400 mg daily	For two years or until disease progression

* Venetoclax must be taken with food approximately at the same time each day. Venetoclax should not be chewed, crushed, or broken prior to swallowing.
Grapefruit and grapefruit juice must be avoided for the duration of treatment.

**Every 28 days for 6 cycles.

The following resources are available for Venetoclax:

- Patient Handout
- Education Bulletin
- Nursing Information
- Pharmacy Information

ULUAVOSIF

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Adverse Events
Osimertinib	Treatment of patients with **epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC)**	Possible adverse events **(any grade):** • Rash or acne • Dry skin • Pruritus • Diarrhea • Paronychia • Cardiomyopathy • QT prolongation • Stomatitis • Decreased appetite • Interstitial lung disease • Elevated alanine aminotransferase (ALT)

Dosing and Administration Information

Pre-medications:

- No pre-medications required

Dosing and Schedule:

- **Oral osimertinib** 80 mg once daily until disease progression.

Additional Protocol Information:

- Grapefruit and grapefruit juice must be avoided for the duration of treatment.

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe or update contact information, please contact:	
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca